LB1027 An adipose-derived stem cell-engineered patch represents a promising treatment for chronic wounds

Mesenchymal stem cell (MSC)-based therapies are emerging as promising approach to treat chronic wounds, although uncontrolled/sub-optimal delivery represents a major threat their wide-spread clinical adoption. Here we report comprehensive pre-clinical evaluation program on the mechanism of action, efficacy and safety an easy-to-use patch that concentrates MSC extracted from human fat (ASCs) in clinical-grade sponge made porcine crosslinked-gelatin. ASC were derived abdominal/skin four ischemic patients. Microarray data revealed grown within upregulate transcription genes important for wound healing, including VEGF, CXCL12 FGF7. The acted both concentrator reservoir ASC-derived factors sponge-derived fragments having healing capacity. ASC-patch promoted dermal fibroblast survival, epidermal epithelialization neovascularization, shown chick chorioallantoic membrane model. No tumor formation was observed immunodeficient Nude mice subcutaneously transplanted with ASC-patch. Finally, ASC-patches prepared syngeneic rats faster re-vascularization full-thickness skin defects pe-clinical rat animal model wounds. Together, provide here compelling evidence patches concentrating ASCs crosslinked gelatin may represent convenient effective tool management